We have previously shown that the anti-lymphoma effects of elraglusib occur below the GSK3α/β IC50, cannot be replicated with other structurally distinct small molecule GSK3 inhibitors, and are unaffected by GSK3A/B knockdown, thereby questioning the role of GSK3 in its mechanism of action (16, 17). This evidence concerns the gene GSK3A and lymphoma.